Dr. Meisel on Sequencing Considerations in First- and Second-Line HER2+ Breast Cancer


In Partnership With:

Jane L. Meisel, MD, discusses sequencing considerations in the first- and second-line settings of HER2-positive breast cancer.

Jane L. Meisel, MD, associate professor, Departments of Hematology and Medical Oncology and Gynecology & Obstetrics, Winship Cancer Institute, Emory University School of Medicine, discusses sequencing considerations in the first- and second-line settings of HER2-positive breast cancer.

Although treatment selection should be individualized for every patient, the first-line standard of care for the majority of patients with HER2-positive breast cancer remains chemotherapy plus trastuzumab (Herceptin) and pertuzumab (Perjeta), says Meisel. Additionally, ado-trastuzumab emtansine (T-DM1; Kadcyla) should be considered for most patients in the second-line setting.

However, patients with significant brain metastases could be given tucatinib (Tukysa) plus trastuzumab and capecitabine (Xeloda) prior to T-DM1, says Meisel. Although the phase 2 HER2CLIMB trial evaluated this combination as a third-line treatment for patients, the FDA indication states it can be used in patients who received at least 1 anti–HER2-based regimen in the metastatic setting. Looking forward, tucatinib is being evaluated in combination with T-DM1 as a second-line option for patients with metastatic HER2-positive breast cancer in the ongoing phase 3 HER2CLIMB-02 trial (NCT03975647), concludes Meisel.

Related Videos
Petros Grivas, MD, PhD, professor, Clinical Research Division, Fred Hutchinson Cancer Center; professor, Division of Hematology and Oncology, University of Washington (UW) School of Medicine; clinical director, Genitourinary Cancers Program, UW Medicine
Somedeb Ball, MBBS, assistant professor, medicine, Division of Hematology Oncology, Department of Medicine, Vanderbilt University Medical Center
Phillip J. Koo, MD
Gabriella Smith, MD
Mikkael A. Sekeres, MD, MS
Francesco Di Meo, PhD
Ko Un “Clara” Park, MD
Naseema Gangat, MBBS
Erin Frances Cobain, MD
Pashtoon Murtaza Kasi, MD, MS